Gut Microbiota and Oral Contraceptive Use in Overweight and Obese Patients with Polycystic Ovary Syndrome

Creative Commons License

EYÜPOĞLU N. D., ERGÜNAY K., AÇIKGÖZ PINAR A., AKYÖN YILMAZ Y., Yilmaz E., Yildiz B. O.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, cilt.105, sa.12, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 105 Sayı: 12
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1210/clinem/dgaa600
  • Dergi Adı: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, EMBASE, Food Science & Technology Abstracts, Gender Studies Database, MEDLINE, Veterinary Science Database
  • Anahtar Kelimeler: microbiome, dysbiosis, oral contraceptive, PCOS, obesity, BACTERIAL, DYSBIOSIS, RISK
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Context: Polycystic ovary syndrome (PCOS) is a common and complex endocrine disorder. Emerging animal and human data point to various changes in microbiota that could be linked with the syndrome. However, the effects of therapeutic approaches on gut microbial composition in women with PCOS remain unknown.